Guillain‐Barré syndrome in a patient with antibodies against SARS‐COV‐2

Helbok, Raimund; Beer, Ronny; Löscher, Wolfgang N.; Boesch, Sylvia; Reindl, Markus; Hornung, Rouven; Schiefecker, Alois Josef; Deisenhammer, Florian; Pfausler, Bettina

doi:10.1111/ene.14388

Cited by 49 publications

(75 citation statements)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On another issue, despite a few GBS cases seemed to have a para-infectious profile [10,37,38,40,55,56] as described for Zika virus [75], all other reported patients developed neurological symptoms with a typical latency after COVID-19 (median time 14 days). This feature, together with the frequently reported negative nasopharyngeal swab at GBS onset [22,24,36,44,45,52] and clinical improvement after IVIG therapy, seems to support According to Brighton diagnostic criteria [66] GBS, the same finding was less frequently reported [84]. However, caution should be warranted in the interpretation of these results, given that MRI findings might have been underestimated, due to lack of a sufficient number of exams in the context of pandemic-imposed restrictions in the routine clinical setting.…”

Section: Discussionmentioning

confidence: 65%

“…One of the two asymptomatic subjects never developed fever, respiratory symptoms, or pneumonia [10], whereas the other patient showed an asymptomatic pneumonia at chest computed tomography (CT) [12]. In all but six patients with available data [22,24,36,44,45,52], SARS-CoV-2 RT-PCR with naso-or oropharyngeal swab or fecal exam was positive at first or following tests. Nevertheless, these six patients tested positive at SARS-CoV-2 serology.…”

Section: Clinical Picture Diagnosis and Therapy Of Covid-19mentioning

confidence: 98%

See 1 more Smart Citation

Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases

et al. 2020

View full text Add to dashboard Cite

Since coronavirus disease-2019 (COVID-19) outbreak in January 2020, several pieces of evidence suggested an association between the spectrum of Guillain-Barré syndrome (GBS) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most findings were reported in the form of case reports or case series, whereas a comprehensive overview is still lacking. We conducted a systematic review and searched for all published cases until July 20th 2020. We included 73 patients reported in 52 publications. A broad age range was affected (mean 55, min 11-max 94 years) with male predominance (68.5%). Most patients showed respiratory and/or systemic symptoms, and developed GBS manifestations after COVID-19. However, asymptomatic cases for COVID-19 were also described. The distributions of clinical variants and electrophysiological subtypes resemble those of classic GBS, with a higher prevalence of the classic sensorimotor form and the acute inflammatory demyelinating polyneuropathy, although rare variants like Miller Fisher syndrome were also reported. Cerebrospinal fluid (CSF) albuminocytological dissociation was present in around 71% cases, and CSF SARS-CoV-2 RNA was absent in all tested cases. More than 70% of patients showed a good prognosis, mostly after treatment with intravenous immunoglobulin. Patients with less favorable outcome were associated with a significantly older age in accordance with previous findings regarding both classic GBS and COVID-19. COVID-19-associated GBS seems to share most features of classic post-infectious GBS and possibly the same immune-mediated pathogenetic mechanisms. Nevertheless, more extensive epidemiological studies are needed to clarify these issues.

show abstract

Section: Discussionmentioning

confidence: 65%

Section: Clinical Picture Diagnosis and Therapy Of Covid-19mentioning

confidence: 98%

Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 4 Auditory Impairment 2 Articles [ 62 ] [ 57 ] 5 NR in all articles. 5 Glossopharyngeal neuralgia 1 Article [ 57 ] 9 NR GBS and other Neuropathies 6 GBS and GBS variants 36 Articles [ 60 ], [ 63 ], [ 101 ], [ 191 ], [ 215 ], [ 218 ], [ 219 ], [ 220 ], [ 221 ], [ 222 ], [ 223 ], [ 224 ], [ 225 ], [ 226 ], [ 227 ], [ 228 ], [ 229 ], [ 230 ] [ 231 ] [ 232 ] [ 233 ] [ 234 ] [ 235 ] [ 236 ], [ 237 ], [ 238 ], [ 239 ], [ 240 ] [ 241 ] [ 242 ], [ 243 ], [ 244 ] [ 245 ] [ 246 ], [ 247 ], [ 248 ] 52 NR in all articles. Su XW et al [ 226 ], reoorted a patient GBS with dysautonomia.…”

Section: Resultsmentioning

confidence: 99%

Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic

Dorche

Huot

Osherov

et al. 2020

Journal of the Neurological Sciences

183

182

View full text Add to dashboard Cite

Coronavirus disease-19 (COVID-19) pandemic continues to grow all over the world. Several studies have been performed, focusing on understanding the acute respiratory syndrome and treatment strategies. However, there is growing evidence indicating neurological manifestations occur in patients with COVID-19. Similarly, the other coronaviruses (CoV) epidemics; severe acute respiratory syndrome (SARS-CoV-1) and Middle East respiratory syndrome (MERS-CoV) have been associated with neurological complications. Methods: This systematic review serves to summarize available information regarding the potential effects of different types of CoV on the nervous system and describes the range of clinical neurological complications that have been reported thus far in COVID-19. Results: Two hundred and twenty-five studies on CoV infections associated neurological manifestations in human were reviewed. Of those, 208 articles were pertinent to COVID-19. The most common neurological complaints in COVID-19 were anosmia, ageusia, and headache, but more serious complications, such as stroke, impairment of consciousness, seizures, and encephalopathy, have also been reported. Conclusion: There are several similarities between neurological complications after SARS-CoV-1, MERS-CoV and COVID-19, however, the scope of the epidemics and number of patients are very different. Reports on the neurological complications after and during COVID-19 are growing on a daily basis. Accordingly, comprehensive knowledge of these complications will help health care providers to be attentive to these complications and diagnose and treat them timely.

show abstract

“…Some cases of polyneuropathy caused by other types of coronavirus have been published in the literature [7 , 8] and some authors support a potential neurotropic role of the virus during the active infection [9] . In the past months a substantial number of case reports of polyneuropathies consistent with GBS during or after infection by COVID-19 have been published [3 , 10 , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] (see supplementary Table 1 and all case report references in the supplementary appendix). To note, the great majority of the cases reported (86.5%) were older than 50 years with a male predominance.…”

Section: Discussionmentioning

confidence: 99%